ArticlePLoS pathogens2014
Timed action of IL-27 protects from immunopathology while preserving defense in influenza.
Article in PLoS pathogens, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 53 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
53 citing papers in PubMed, 75 citations in OpenAlex.
- Current insights into bacterial secondary infection following influenza A virus infection.Frontiers in microbiology · 2026Review
- CXCR3 ameliorates neutrophil-dependent disease severity in SARS-CoV-2 infection by regulating CD4Frontiers in immunology · 2026Article
- Interleukin-27 is antiviral against Zika virus at the maternal-fetal interface.Nature communications · 2025Article
- IL-27 limits HSPC differentiation during infection and protects from stem cell exhaustion.eLife · 2025Article
- Interleukin-27 is antiviral at the maternal-fetal interface.Research square · 2025Article
- Role of IL-27 in COVID-19: A Thin Line between Protection and Disease Promotion.International journal of molecular sciences · 2024Review
- Article
- Article
- Article
- COVID-19 immune signatures in Uganda persist in HIV co-infection and diverge by pandemic phase.Nature communications · 2024Article
- IL-27 expression regulation and its effects on adaptive immunity against viruses.Frontiers in immunology · 2024Review
- Role of IL-27 in HSV-1-Induced Herpetic Stromal Keratitis.Journal of immunology (Baltimore, Md. : 1950) · 2023Article
- Antiviral response and immunopathogenesis of interleukin 27 in COVID-19.Archives of virology · 2023Article
- CD11a regulates hematopoietic stem and progenitor cells.Frontiers in immunology · 2023Article
- The Analyses of Cetacean Virus-Responsive Genes Reveal Evolutionary Marks in Mucosal Immunity-Associated Genes.Biochemical genetics · 2022Article
- Enhancing Prednisone-Based Arthritis Therapy with Targeted IL-27 Gene Delivery.Bioengineering (Basel, Switzerland) · 2022Article
- IL-27 Induces CCL5 Production by T Lymphocytes, Which Contributes to Antitumor Activity.Journal of immunology (Baltimore, Md. : 1950) · 2022Article
- Time-Dependent Increase in Susceptibility and Severity of Secondary Bacterial Infection during SARS-CoV-2 Infection.bioRxiv : the preprint server for biology · 2022Article
- The interplay between SARS-CoV-2 infected airway epithelium and immune cells modulates regulatory/inflammatory signals.iScience · 2022Article
- Antiviral Activities of Interleukin-27: A Partner for Interferons?Frontiers in immunology · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
16 authors at 6 institutions in 2 countries.
Funding
Abstract
Infection with influenza virus can result in massive pulmonary infiltration and potentially fatal immunopathology. Understanding the endogenous mechanisms that control immunopathology could provide a key to novel adjunct therapies for this disease. Here we show that the cytokine IL-27 plays a crucial role in protection from exaggerated inflammation during influenza virus infection. Using Il-27ra-/- mice, IL-27 was found to limit immunopathology, neutrophil accumulation, and dampened TH1 or TH17 responses via IL-10-dependent and -independent pathways. Accordingly, the absence of IL-27 signals resulted in a more severe disease course and in diminished survival without impacting viral loads. Consistent with the delayed expression of endogenous Il-27p28 during influenza, systemic treatment with recombinant IL-27 starting at the peak of virus load resulted in a major amelioration of lung pathology, strongly reduced leukocyte infiltration and improved survival without affecting viral clearance. In contrast, early application of IL-27 impaired virus clearance and worsened disease. These findings demonstrate the importance of IL-27 for the physiological control of immunopathology and the potential value of well-timed IL-27 application to treat life-threatening inflammation during lung infection.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.